Clinical Trials Logo

Bile Duct Adenocarcinoma clinical trials

View clinical trials related to Bile Duct Adenocarcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT06092645 Recruiting - Clinical trials for Bile Duct Adenocarcinoma

Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma

Start date: October 30, 2023
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, multicenter Phase II clinical study to evaluate the efficacy and safety of surufatinib combined with cardanilimab in second-line treatment of patients with inoperable or metastatic bile duct adenocarcinoma

NCT ID: NCT04042831 Recruiting - Clinical trials for Bile Duct Adenocarcinoma

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Start date: June 24, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03117855 Withdrawn - Clinical trials for Stage III Intrahepatic Cholangiocarcinoma

Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Start date: December 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects of capecitabine and Y-90 radioembolization in treating patients with bile duct cancer in the liver that has spread to other places in the body and cannot be removed by surgery. Radiation therapy, such as Y-90 radioembolization, injects tiny radioactive Y-90 microspheres into the blood supply next to the liver tumors to kill tumor cells. Capecitabine may make radiation more effective. Giving capecitabine and Y-90 radioembolization may work better in treating patients with bile duct cancer in the liver.